Author

D. R. Harris

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:proteomics· 2 Assay:cryo-EM· 1 Organism:mouse· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

A. S. Olia· 3 shared P. D. Kwong· 3 shared A. Pegu· 2 shared E. S. Yang· 2 shared J. Misasi· 2 shared J. R. Mascola· 2 shared K. Leung· 2 shared L. Wang· 2 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. S. Olia

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization

J. Misasi, R. R. Wei, L. Wang, A. Pegu, C.-J. Wei, O. Oloniniyi, T. Zhou, J. I. Moliva, B. Zhao, M. Choe, E. S. Yang, Y. Zhang, M. Boruszczak, M. Chen, K. Leung, , N. J. Sullivan

This paper develops multispecific antibodies that neutralize all SARS-CoV-2 variants, including Omicron, by targeting multiple epitopes on the spike protein.

bioRxiv · Jul 29, 2022 · PreprintImmunology

Potent and pan-neutralization of SARS-CoV-2 variants of concern by DARPins

V. K. Chonira, Y.-D. Kwon, J. Gorman, J. B. Case, Z. Ku, R. Simeon, R. G. Casner, D. R. Harris, A. S. Olia, T. Stevens, L. Shapiro, H. Boyd, Y. Tsybovsky, F. Krammer, M. Diamond, , Z. Chen

This paper reports the development of two DARPins, FSR16m and FSR22, that potently neutralize SARS-CoV-2 variants, including emerging ones, with efficacy comparable to therapeutic antibodies.

bioRxiv · May 30, 2022 · PreprintBioengineering

Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529

T. Zhou, L. Wang, J. Misasi, A. Pegu, Y. Zhang, D. R. Harris, A. S. Olia, C. A. Talana, E. S. Yang, M. Chen, M. Choe, W. Shi, I.-T. Teng, A. Creanga, C. Jenkins, , P. D. Kwong

The paper identifies potent monoclonal antibodies that neutralize the B.1.1.529 SARS-CoV-2 variant and reveals structural mechanisms enabling their effectiveness.

bioRxiv · Dec 27, 2021Immunology